Full text
Earnings transcript
Read the complete earnings call transcript.
BMY
Bristol-Myers Squibb Company
$56.48
0
(0%)
| Exchange: | NYSE |
| Market Cap: | 115.336B |
| Shares Outstanding: | 2.136B |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Christopher S. Boerner | |||||
| Full Time Employees: | 34100 | |||||
| Address: |
| |||||
| Website: | https://www.bms.com |
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company’s therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 45,006,000 | 48,300,000 | 48,194,000 |
| Gross Profit | 25,357,000 | 27,432,000 | 32,602,000 |
| EBITDA | 19,366,000 | 3,168,000 | 14,545,000 |
| Operating Income | 8,472,000 | 9,658,000 | 12,696,000 |
| Net Income | 8,025,000 | -8,948,000 | 7,053,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 95,159,000 | 92,603,000 | 90,038,000 |
| Total Liabilities | 65,674,000 | 76,215,000 | 71,532,000 |
| Total Stockholders Equity | 29,430,000 | 16,335,000 | 18,473,000 |
| Total Debt | 41,464,000 | 51,200,000 | 48,965,000 |
| Cash and Cash Equivalents | 11,464,000 | 10,346,000 | 10,209,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 13,860,000 | 15,190,000 | 14,156,000 |
| Capital Expenditure | -1,209,000 | -1,248,000 | -1,311,000 |
| Free Cash Flow | 12,651,000 | 13,942,000 | 12,845,000 |
| Net Income | 8,040,000 | -8,933,000 | 7,055,000 |
| Net Change in Cash | 2,194,000 | -1,172,000 | -137,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 36,062,429.342 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 37,242,616.073 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 36,657,227.094 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 11,884,846.702 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 12,273,792.723 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 12,080,870.105 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 9,511,447.794 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 9,918,117.044 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 9,716,405.014 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 5,904,449.352 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 6,097,679.617 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 6,001,834.727 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 4.760 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 4.860 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 4.660 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 11 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 3 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Financial Performance: Bristol-Myers Squibb reported robust financial results in the Q3 2025 earnings call, with total company sales demonstrating significant growth compared to prior periods. Key metrics such as revenue and net income reflect a solid operational foundation, supported by consistent operating cash flow as per the latest income and cash flow statements.
- Strategic Growth Focus: The company highlighted a clear strategic emphasis on expanding its product portfolio and pipeline during the earnings call, which aligns with sustained gross profit margins and positive free cash flow yield (as per Key Metrics TTM). This indicates effective capital allocation and potential for reinvestment in innovation.
- Market Position and Scale: With a substantial market capitalization and a presence in the pharmaceutical industry (as per Company Profile), BMY benefits from economies of scale, a diversified revenue base across product and geographic segments, and a workforce of significant size, enhancing operational resilience.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates BMY intrinsic value between $77.34 – $101.21 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about BMY valuation
Is Bristol-Myers Squibb Company (BMY) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Bristol-Myers Squibb Company (BMY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is BMY a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BMY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is BMY’s P/E ratio?
You can see BMY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for BMY?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is BMY a good long-term investment?
Whether BMY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
BMY
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0
Trading Metrics:
| Open: | 56.64 | Previous Close: | 56.48 | |
| Day Low: | 56.1 | Day High: | 56.66 | |
| Year Low: | 42.52 | Year High: | ||
| Price Avg 50: | Price Avg 200: | |||
| Volume: | Average Volume: |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
Relevant news
